Huntington's disease (HD) is a devastating autosomal dominant neurodegenerative disorder leading to progressive motor and cognitive decline with neuropsychiatric disturbance. It has a mean age of onset of 42 years of age and affects people in the prime of life.
Sarah Tabrizi's multidisciplinary research has made seminal discoveries in HD. Tabrizi's research findings have provided transformational insights into the biology of HD and helped create an entirely new field of novel therapeutic agents.
Her work balances the investigation of fundamental mechanistic science combined with human clinical research in patients, and she has redefined the lifelong trajectory of this fatal disease, making it one that is now therapeutically tractable. Her research has led to the first treatment trials of nucleic acid therapies in HD, and other adult brain disorders.
Tabrizi's research has been recognised by numerous major prizes including the 2017 Leslie Gehry Brenner Prize for Innovation in Science, 2019 Yahr Award, 2022 Osler Medal, 2022 HD Society of America Research Award, the 2022 MRC Millennium Medal, and the 2023 Arvid Carlsson Award.
Professional position
- Professor of Clinical Neurology and Neurogenetics, Department of Neurodegenerative Disease, University College London (UCL)
Subject groups
-
Molecules of Life
Biochemistry and molecular biology, Cell biology (incl molecular cell biology)
-
Cell Biology
Cellular pathology, Genetics (excluding population genetics)
-
Multicellular Organisms
Behavioural neuroscience, Cellular neuroscience, Pharmacology (non-clinical), Physiology and medicine (non-clinical)
-
Health and Human Sciences
Clinical neuroscience, Clinical pathology, Clinical pharmacology, Clinical physiology, Medicine, clinical studies, Molecular medicine
